StockWatch
·

DIVI'S LABORATORIES LTD.

BSE: 532488

P/L Snapshot

Q2 FY27 · standalone

vs Q1 FY27·vs Q2 FY26
Revenue
3.7K
+23.0%+33.1%
Expenditure
2.2K
+18.3%+17.4%
Net Profit
1.1K
+27.9%+63.8%
OPM %
43.52%
+1.83pp+9.87pp

Shareholding

Pattern breakdown

P/L Trends

(in crores)

RevenueExpenditureNet Profit
0.001.0K2.1K3.1K4.2KQ2 FY25Q3 FY25Q4 FY25Q1 FY26Q2 FY26Q3 FY26Q4 FY26Q1 FY27Q2 FY27
Price Chart
Reports

The Validation Batch Hangover: 35% Growth, 10% Base Business

validation batches · capex projects · peptides

Result verdictFollow-upQ2 FY2713 Nov 20266 minPharma & Healthcare

Strong growth, validation batches mask base business headwinds

validation batches · capex projects · peptides

TranscriptDeep diveQ2 FY2713 Nov 20266 minPharma & Healthcare

Divi's Labs consolidated PAT surges 64% YoY to ₹1,127 Cr, margins hit record 42.6%

pharma api · custom synthesis · margin expansion

ResultsQ2 FY2707 Nov 20263 minPharma & Healthcare
Latest
Quarterly Result7 Nov, 12:00 pm

Divi's Labs consolidated PAT surges 64% YoY to ₹1,127 Cr, margins hit record 42.6%

Divi's Laboratories posted consolidated total income of ₹3,770 Cr for Q2 FY27, with revenue from operations up 35.4% YoY (and 19.4% QoQ) to ₹3,676 Cr, and PAT up 63.6% YoY (24.9% QoQ) to ₹1,127 Cr. The print clears the pre-result preview's on-plan range on every count: revenue (₹3,100–3,200 Cr expected vs ₹3,676 Cr actual), EBITDA margin (38–41% expected vs ~42.6% actual) and PAT (₹800–900 Cr expected vs ₹1,127 Cr actual) — resolving the Street's Q1-era debate (level-change vs peak) in favour of a level change, at least for this quarter. It also clears management's own August guidance of "double-digit FY27 revenue growth" and EBITDA "similar to FY26" by a wide margin — FY26's full-year EBITDA margin ran near 32–33%, roughly 10 percentage points below this quarter's print. The margin expansion is broad-based rather than a single line item: gross margin (revenue less material cost and inventory movement) works out to roughly 68%, well above the ~60% management flagged for the year, helped by a ₹631 Cr build in finished-goods/WIP inventory that reduced the reported cost-of-materials line. EBITDA margin (OPM) expanded to ~42.6% from 32.7% a year ago and 40.8% last quarter, while net margin improved to 29.9% from 24.1% YoY and 28.7% QoQ — both metrics trending up sequentially for a second straight quarter, not just a one-off pop. H1 FY27 consolidated PAT stands at ₹2,029 Cr on revenue of ₹6,756 Cr, up 64.5% and 31.8% respectively over H1 FY26, confirming this isn't a single-quarter anomaly after Q1's similarly strong ₹902 Cr PAT (+66% YoY, per the prior release). Standalone tracks consolidated closely (PAT ₹1,140 Cr, +63.8% YoY), so there's no meaningful standalone-vs-consolidated story to flag. The company's own press release is a factual recap of the total income/PBT/PAT figures with no incremental qualitative commentary on drivers or outlook beyond what was already said on the August concall; the board otherwise used the November 7 meeting only to approve the results and press release, with no other business items disclosed in this filing. What this sets up: management's prior capex update (three projects ~70% capitalised, ₹1,400 Cr of ₹2,000 Cr) is broadly consistent with CWIP declining to ₹1,638 Cr from ₹2,113 Cr at FY26-end as PP&E rose to ₹7,452 Cr — capitalisation is progressing, though this filing doesn't break out project-level capex to confirm the exact 70% figure.

7 Nov 2026, 12:00 pm

Corporate Events

Board MeetingDIVISLAB
2026
7Nov

Board Meeting

The meeting of the Board of Directors is scheduled to consid…

BSE Filing ↗
Board MeetingDIVISLAB
2026
10Aug

Board Meeting

The 36th Annual General Meeting (AGM) of the Company is sche…

BSE Filing ↗
DividendDIVISLAB
2026
3Aug

₹30 / share

BSE Filing ↗
Board MeetingDIVISLAB
2026
1Aug

Board Meeting

A meeting of the Board of Directors of the Company is schedu…

BSE Filing ↗
DividendDIVISLAB
2026
24Jul

₹30 / share

BSE Filing ↗
Board MeetingDIVISLAB
2024
3Aug

Board Meeting

Consider and approve the standalone and consolidated unaudit…

BSE Filing ↗
Board MeetingDIVISLAB
2024
25May

Board Meeting

Consider and approve audited standalone and consolidated fin…

BSE Filing ↗
Board MeetingDIVISLAB
2024
10Feb

Board Meeting

Consider and approve the standalone and consolidated unaudit…

BSE Filing ↗
Board MeetingDIVISLAB
2023
6Nov

Board Meeting

Consider and approve standalone and consolidated unaudited f…

BSE Filing ↗
Board MeetingDIVISLAB
2023
14Aug

Board Meeting

Consider and approve the standalone and consolidated unaudit…

BSE Filing ↗